These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 22526302

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
    Chono K, Katsumata K, Kontani T, Shiraki K, Suzuki H.
    Biochem Pharmacol; 2012 Aug 15; 84(4):459-67. PubMed ID: 22687623
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo.
    Himaki T, Masui Y, Chono K, Daikoku T, Takemoto M, Haixia B, Okuda T, Suzuki H, Shiraki K.
    Antiviral Res; 2012 Feb 15; 93(2):301-304. PubMed ID: 22155691
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
    Katsumata K, Chono K, Suzuki H.
    Biochem Pharmacol; 2018 Dec 15; 158():201-206. PubMed ID: 30365949
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
    Collot M, Rouard C, Brunet C, Agut H, Boutolleau D, Burrel S.
    Antiviral Res; 2016 Apr 15; 128():1-6. PubMed ID: 26826441
    [Abstract] [Full Text] [Related]

  • 14. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
    Takada A, Katashima M, Kaibara A, Sawamoto T, Zhang W, Keirns J.
    Clin Pharmacol Drug Dev; 2014 Sep 15; 3(5):365-70. PubMed ID: 27129009
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
    Duan J, Liuzzi M, Paris W, Liard F, Browne A, Dansereau N, Simoneau B, Faucher AM, Cordingley MG.
    Antimicrob Agents Chemother; 2003 Jun 15; 47(6):1798-804. PubMed ID: 12760851
    [Abstract] [Full Text] [Related]

  • 17. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
    Chono K, Katsumata K, Suzuki H, Shiraki K.
    Antiviral Res; 2013 Feb 15; 97(2):154-60. PubMed ID: 23261844
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
    Uhlig N, Donner AK, Gege C, Lange F, Kleymann G, Grunwald T.
    Antiviral Res; 2021 Nov 15; 195():105190. PubMed ID: 34666109
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.